Drug Trial Radar · NCT07300085
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
710
Planned (sponsor's estimate)
Start
Nov 8, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). Researchers are looking for other ways to prevent severe illness from the influenza virus. The goals of this study are to learn if: * MK-1406 (formerly CD388) is safe to take with Fluzone® * MK-1406 affects the immune response to Fluzone®
Conditions
- Healthy Participants
Interventions
Fluzone® High-Dose (HD) influenza vaccineBiological
Fluzone® HD injectable suspension administered by intramuscular (IM) injection
MK-1406 InjectionCombination product
MK-1406 liquid for injection administered subcutaneously
PlaceboCombination product
MK-1406 matched liquid for SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean of Hemagglutinin Inhibition (HAI) Titers Against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® High-Dose (HD) and MK-1406 Compared to Participants Who Receive Fluzone® HD and PlaceboTime frame: Predose (Day 1), Day 15 and Day 29
- Percentage of Participants with Seroconversion Rates against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® HD and MK-1406 Compared to Participants Who Receive Fluzone® HD and PlaceboTime frame: Predose (Day 1), Day 15 and Day 29
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Foothills Research Center ( Site 0010)
Phoenix, Arizona · Recruiting
Parexel ( Site 0001)
Glendale, California · Recruiting
Flourish Research ( Site 0014)
Miami, Florida · Recruiting
South Florida Research Center, Inc ( Site 0009)
Miami, Florida · Recruiting
DelRicht Research ( Site 0005)
New Orleans, Louisiana · Recruiting
Parexel ( Site 0002)
Baltimore, Maryland · Recruiting
DelRicht Research ( Site 0012)
Gulfport, Mississippi · Recruiting
Drug Trials America ( Site 0006)
Hartsdale, New York · Recruiting
Rochester Clinical Research, Inc. ( Site 0008)
Rochester, New York · Recruiting
DelRicht Research ( Site 0015)
Charlotte, North Carolina · Recruiting
Tekton Research, LLC. ( Site 0007)
Oklahoma City, Oklahoma · Recruiting
Epic Clinical Research ( Site 0003)
Lewisville, Texas · Recruiting
Elevate Clinical Research - McAllen ( Site 0013)
McAllen, Texas · Recruiting
Clinical Trials of Texas, LLC-Clinical Research ( Site 0004)
San Antonio, Texas · Recruiting
Texas Health Care ( Site 0011)
Stephenville, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.